Stockscreener 앱 받기
87.35
0.45%
0.39
시간 외 거래:
87.35
전일 마감가:
$86.96
열려 있는:
$88.42
하루 거래량:
1.74M
Relative Volume:
1.09
시가총액:
$43.27B
수익:
$9.93B
순이익/손실:
$1.12B
주가수익비율:
38.82
EPS:
2.25
순현금흐름:
$1.58B
1주 성능:
-0.15%
1개월 성능:
+3.04%
6개월 성능:
+3.53%
1년 성능:
-2.94%
1일 변동 폭
$86.97
$88.42
1주일 범위
$85.52
$88.42
52주 변동 폭
$80.48
$101.10
Alcon Inc Stock (ALC) Company Profile
ALC을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
ALC
Alcon Inc
|
87.35 | 43.27B | 9.93B | 1.12B | 1.58B | 2.25 |
|
ISRG
Intuitive Surgical Inc
|
518.62 | 183.53B | 8.71B | 2.48B | 1.75B | 6.82 |
|
BDX
Becton Dickinson Co
|
178.85 | 50.43B | 20.87B | 1.50B | 2.59B | 5.24 |
|
RMD
Resmed Inc
|
257.92 | 37.30B | 5.02B | 1.31B | 1.56B | 8.91 |
|
WST
West Pharmaceutical Services Inc
|
210.89 | 16.32B | 2.90B | 467.20M | 306.90M | 6.37 |
Alcon Inc Stock (ALC) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2025-05-20 | 다운그레이드 | Deutsche Bank | Buy → Hold |
| 2025-05-14 | 재확인 | BTIG Research | Buy |
| 2025-03-28 | 재확인 | Needham | Buy |
| 2025-03-25 | 업그레이드 | BofA Securities | Neutral → Buy |
| 2025-01-24 | 재확인 | Needham | Buy |
| 2025-01-10 | 업그레이드 | Redburn Atlantic | Neutral → Buy |
| 2024-12-17 | 재확인 | Needham | Buy |
| 2024-11-12 | 재확인 | Needham | Buy |
| 2024-10-10 | 업그레이드 | Redburn Atlantic | Sell → Neutral |
| 2024-09-10 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2024-07-15 | 업그레이드 | Morgan Stanley | Underweight → Equal-Weight |
| 2024-05-15 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2024-04-10 | 개시 | Goldman | Buy |
| 2024-03-14 | 개시 | RBC Capital Mkts | Sector Perform |
| 2024-02-06 | 재개 | KeyBanc Capital Markets | Overweight |
| 2024-01-23 | 개시 | Bernstein | Outperform |
| 2023-12-18 | 다운그레이드 | Redburn Atlantic | Neutral → Sell |
| 2023-12-12 | 개시 | Stifel | Buy |
| 2023-12-04 | 다운그레이드 | Morgan Stanley | Equal-Weight → Underweight |
| 2023-08-17 | 업그레이드 | JP Morgan | Neutral → Overweight |
| 2023-05-30 | 재개 | Morgan Stanley | Equal-Weight |
| 2023-05-10 | 업그레이드 | Robert W. Baird | Neutral → Outperform |
| 2023-03-01 | 업그레이드 | Societe Generale | Sell → Hold |
| 2022-12-22 | 개시 | Mizuho | Buy |
| 2022-11-17 | 다운그레이드 | Societe Generale | Hold → Sell |
| 2022-08-11 | 다운그레이드 | Societe Generale | Buy → Hold |
| 2022-05-13 | 재개 | Credit Suisse | Outperform |
| 2022-05-12 | 업그레이드 | Stephens | Equal-Weight → Overweight |
| 2022-04-08 | 개시 | Needham | Buy |
| 2022-03-11 | 개시 | BofA Securities | Buy |
| 2022-01-18 | 다운그레이드 | Stephens | Overweight → Equal-Weight |
| 2022-01-07 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2021-10-01 | 개시 | Oppenheimer | Perform |
| 2021-07-14 | 개시 | Deutsche Bank | Buy |
| 2021-05-06 | 업그레이드 | Citigroup | Sell → Neutral |
| 2021-03-22 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2020-11-12 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2020-07-06 | 다운그레이드 | Citigroup | Neutral → Sell |
| 2020-07-06 | 개시 | KeyBanc Capital Markets | Sector Weight |
| 2020-06-16 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2020-04-08 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2020-03-26 | 업그레이드 | Argus | Hold → Buy |
| 2020-03-24 | 업그레이드 | Societe Generale | Sell → Hold |
| 2020-03-13 | 업그레이드 | UBS | Neutral → Buy |
| 2020-03-05 | 개시 | Citigroup | Neutral |
| 2020-02-26 | 업그레이드 | Berenberg | Hold → Buy |
| 2020-01-08 | 개시 | Argus | Hold |
| 2019-10-29 | 개시 | Stephens | Equal-Weight |
| 2019-08-21 | 재확인 | BofA/Merrill | Neutral |
| 2019-06-24 | 개시 | SVB Leerink | Mkt Perform |
| 2019-06-14 | 개시 | BTIG Research | Neutral |
| 2019-05-10 | 개시 | Robert W. Baird | Outperform |
| 2019-05-02 | 개시 | Credit Suisse | Outperform |
모두보기
Alcon Inc 주식(ALC)의 최신 뉴스
What drives Alcon Inc. stock priceSuperior stock selection - Jammu Links News
What analysts say about Alcon Inc. stockTriple-digit profit margins - Autocar Professional
Is Alcon Inc. a good long term investmentHigh-yield portfolio picks - Jammu Links News
Alcon Inc. Stock Analysis and ForecastAccelerated investment success - Jammu Links News
September 19th Options Now Available For Alcon (ALC) - Nasdaq
Alcon Stock Gains Following UNITY VCS' Approval in Canada - MSN
Alcon’s Clareon PanOptix Pro IOL approved in Canada for cataract patients - Ophthalmology Times Europe
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target - Investing.com Nigeria
Leadership watch: ViaLase, J&J, Alcon, and myze make executive additions - Eyes On Eyecare
Stifel reiterates Buy rating on Alcon stock, maintains $100 price target By Investing.com - Investing.com South Africa
Alcon Adds Noninvasive Treatment Solution, Acquires LumiThera | Business | Jul 2025 - Photonics Spectra
Alcon Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - VisionMonday.com
Alcon sees the light with Lumithera buy for dry AMD - BioWorld MedTech
Alcon’s vitreoretinal-cataract system receives Health Canada approval By Investing.com - Investing.com South Africa
Alcon to acquire LumiThera for dry AMD treatment device - MSN
Alcon to purchase LumiThera - Eyes On Eyecare
Alcon's Unity VCS Gets Health Canada Approval - Nasdaq
Alcon snaps up LumiThera for light-based AMD treatment - Optics.org
Alcon Gets Health Canada Approval on Unity Vitreoretinal Cataract System - MarketScreener
Alcon’s vitreoretinal-cataract system receives Health Canada approval - Investing.com
Alcon : Names Julie M. Brewer to its Executive Leadership Team as SVP, President, Global Franchises - MarketScreener
Alcon’s Latest Breakthrough Surgical Technology, Unity VCS, receives Health Canada approval - Nasdaq
La dernière technologie chirurgicale révolutionnaire d’Alcon, Unity VCS, reçoit l’approbation de Santé Canada - New Castle News
Alcon Eyes Vitreoretinal Surgery Market Expansion in LumiThera Deal - MarketScreener
Alcon to acquire LumiThera and its dry AMD light therapy device - Investing.com Australia
Alcon Inc (ALC) Announces Approval of Clareon PanOptix Pro Intraocular Lens - MSN
Alcon's Bold Bet on Light Therapy: A New Dawn for Dry AMD and Retinal Dominance - AInvest
Alcon To Acquire LumiThera - citybiz
Alcon to acquire LumiThera and its photobiomodulation device for the treatment of dry AMD - Ophthalmology Times
Alcon To Acquire LumiThera And Its Photobiomodulation Device - Nasdaq
Alcon to acquire LumiThera and its dry AMD light therapy device By Investing.com - Investing.com South Africa
Alcon to Acquire LumiThera and Its Photobiomodulation Device for the Treatment of Early and Intermediate Dry Age-Related Macular Degeneration (AMD) - Business Wire
Do Options Traders Know Something About Alcon Stock We Don't? - MSN
Is it Apt to Retain Alcon Stock in Your Portfolio for Now? - MSN
Analysts Are Bullish on These Healthcare Stocks: Alcon (ALC), Medtronic (MDT) - The Globe and Mail
Alcon Canada Earns Global Recognition as a Top Employer - Yahoo Finance
Alcon Introduces Clareon PanOptix Pro in Canada, Delivering the Lowest Light Scatter of any Trifocal IOL - Yahoo Finance
Alcon and Merit Medical: Creating Regulatory and Quality Business Value with AI - Veeva
Should Weakness in Alcon Inc.'s (VTX:ALC) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials? - simplywall.st
GLP-1 Drugs Show Promise in Reducing Risk of Age-Related Eye Diseases - Managed Healthcare Executive
Alcon Gets First FDA Approval Since Novartis Spinoff - Orange County Business Journal
Alcon’s Tryptyr Adds Growth, But Valuation Keeps Shares On 'Hold' (NYSE:ALC) - Seeking Alpha
Alcon Stock Rated Buy by BTIG Following TRYPTYR Approval - MSN
Phacoemulsification Devices Market Is Booming Worldwide - openPR.com
Alcon: Achieving UDI Compliance with Veeva RIM - Veeva
Alcon (ALC) Receives Increased Price Target from Citi | ALC Stoc - GuruFocus
Alcon Inc (ALC) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.58%
1.13%
자본화:
|
볼륨(24시간):